Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Catalyst Pharmaceuticals excels in 2022, eyes sustained growth in epilepsy market

Catalyst Pharmaceuticals delivered exceptional financial performance in 2022, with strong revenue growth and strategic acquisitions positioning the company for continued success.
While facing challenges in maintaining sequential quarterly revenue growth, Catalyst's focus on innovation, patient care, and financial stability presents opportunities for sustained growth.
Overall, Catalyst's industry leadership, financial strength, and commitment to expanding product access and market presence underscore its potential for future growth and success.

Catalyst Pharmaceuticals reports record Q1 earnings, eyes growth opportunities

Catalyst Pharmaceuticals delivered exceptional financial results in Q1 2023, with strong revenue growth and a healthy cash position, positioning the company for continued success.
While facing challenges such as seasonal sales trends and diagnosis rates, the company's strategic focus on acquisitions and market expansion presents promising opportunities for future growth.
With a clear commitment to organic growth, product integration, and market penetration, Catalyst Pharmaceuticals remains poised for sustained performance and market leadership.

Catalyst Pharmaceuticals excels in Q2, eyes global expansion and new treatments

Catalyst Pharmaceuticals delivered strong financial performance in Q2 2023, driven by revenue growth and strategic initiatives.
While facing challenges in patient identification and treatment, the company remains focused on expansion and innovation in rare disease therapeutics.
Opportunities lie in upcoming product launches, global expansion, and collaboration efforts to drive future growth and market penetration.

Catalyst Pharmaceuticals (CPRX) excels in Q3, eyes global expansion

Catalyst Pharmaceuticals (CPRX) demonstrated robust financial performance in Q3 2023, driven by strong product revenues and strategic initiatives.
While facing challenges in managing launch expenses and regulatory processes, CPRX remains focused on leveraging growth opportunities through global expansion and portfolio enhancements.
With a new CEO appointment and a clear focus on market expansion and innovation, CPRX is poised for sustained growth and value creation in the pharmaceutical sector.

Catalyst Pharmaceuticals posts record revenues, eyes growth in rare diseases

Catalyst Pharmaceuticals delivered strong financial performance in 2023, driven by record revenues and strategic acquisitions.
While facing challenges with FYCOMPA's growth and upcoming patent expiry, the company remains well-positioned for growth in rare disease markets.
Opportunities lie in the launch of AGAMREE, expansion into new therapeutic areas, and leveraging the stickiness of epilepsy drugs post-patent expiry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Catalyst Pharmaceuticals (CPRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Catalyst Pharmaceuticals (CPRX) Jumps: Stock Rises 5.5%

BioDelivery Sciences

BioMarin Pharmaceutical

Innoviva

Novavax

Vertex Pharmaceuticals

Vaxart

Voyager Therapeutics

These are the biotech stocks with the best value, fastest growth, and most momentum for Q1 2021.

Top Biotech Stocks for Q1 2021

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

Why Is Catalyst (CPRX) Up 4.4% Since Last Earnings Report?

Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q3 2020 Results - Earnings Call Transcript

Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2020.

Catalyst's (CPRX) Q3 Earnings Beat Estimates, Revenues Miss

Catalyst (CPRX) delivered earnings and revenue surprises of 22.22% and -6.10%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings Estimates

- Firdapse® Third Quarter Net Revenues of $ 29. 2 Million

Catalyst Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update

Catalyst (CPRX) will provide updates on earnings and revenues when its releases third-quarter 2020 results.

Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?

Catalyst Pharmaceuticals stock has been on a wild ride since its drug got FDA approval -- and despite legal drama, it may be worth the risk. The post Despite Legal Drama, Catalyst Pharmaceuticals Looks Oversold appeared first on InvestorPlace.

Despite Legal Drama, Catalyst Pharmaceuticals Looks Oversold

CORAL GABLES, Fla., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it will release third quarter 2020 financial results after market close on Monday, November 9, 2020. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. ET on Tuesday, November 10, 2020 to discuss the financial results and to provide a corporate update.

Catalyst Pharmaceuticals to Hold Third Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, November 10th, 2020

Perdoceo Education

Sabine Royalty Trust

Vanda Pharmaceuticals

XBiotech

As markets continue sliding on economic recovery slowdown fears, five Ben Graham Lost Formula stocks with high financial strength are Sabine Royalty Trust (NYSE:SBR), XBiotech Inc. (NASDAQ:XBIT), Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) and Perdoceo Education Corp. (NASDAQ:PRDO) according to the All-in-One Screener, a Premium feature of GuruFocus.

5 Ben Graham Lost Formula Stocks With High Financial Strength

Typically, a major clinical victory would boost names like Catalyst Pharmaceuticals stock. Unfortunately, some political rumblings and an unexpected competitor got in the way of CPRX.

Why Catalyst Pharmaceuticals Stock Is Feeling the ‘Bern'

CORAL GABLES, Fla., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it has filed a lawsuit in the U.S. District Court for New Jersey against Jacobus Pharmaceuticals, Inc. (Jacobus), and a lawsuit in the U.S. District Court for the Western District of Pennsylvania against PantherRx Rare LLC (PantherRx) for infringement of U.S. Patent No. 10,793,893 (the '893 patent). The '893 patent is exclusively licensed to Catalyst Pharmaceuticals and covers certain methods for treating disease using amifampridine drug products, including Catalyst's Firdapse® product, in patients who are slow metabolizers of amifampridine.

Catalyst Pharmaceuticals Announces Filing of Patent Infringement Actions Against Jacobus Pharmaceuticals and PantherRx

Catalyst Pharmaceuticals Has Potential To Push Higher If They Can Overcome Current Headwinds

Issued Patent is the First Covering Firdapse® Issued Patent is the First Covering Firdapse®

Catalyst Pharmaceuticals Announces Issuance of U.S. Patent for Firdapse®

CORAL GABLES, Fla., Sept.  29, 2020  (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that the federal judge handling Catalyst's case against the FDA has adopted the previously reported Report and Recommendation of the Magistrate Judge, granted summary judgment in favor of the FDA and Jacobus, and dismissed Catalyst's case. Catalyst is currently reviewing the District Judge's decision, which it believes to be erroneous, and intends to appeal the result to the Eleventh Circuit Court of Appeals.

Catalyst Pharmaceuticals Announces Ruling on Lawsuit against the FDA and Intent to Appeal

Investors often get excited about small-cap biotech and emerging pharmaceutical stocks because the upside can be exponential if their drugs and treatments become a hit.

Catalyst Pharmaceuticals Looks Cheap, but Few Catalysts for Massive Upside

Why Is Catalyst (CPRX) Down 7.5% Since Last Earnings Report?

Catalyst can't seem to catch a break in the clinic these days.

Why Catalyst Pharmaceuticals Stock Crashed in August

Catalyst's (CPRX) efforts to expand Firdapse label are encouraging. However, with only a few candidates in the pipeline, the company's dependence on Firdapse for growth remains a matter of concern.

Catalyst (CPRX) Eyes Firdapse Label Expansion Amid Competition

Notice of Application for Judicial Review Filed Today in the Federal Court of Canada Notice of Application for Judicial Review Filed Today in the Federal Court of Canada

KYE Pharmaceuticals and Catalyst Pharmaceuticals Challenge Health Canada’s Decision to Overlook Firdapse® Data Exclusivity

CORAL GABLES, Fla., Aug.  18, 2020  (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, and KYE Pharmaceuticals Inc. ("KYE"), a private company headquartered in Mississauga, Ontario and focused on bringing medicines that fulfill clinically significant unmet needs to the Canadian market, today announced that the companies have entered into an exclusive license agreement under which KYE will commercialize Firdapse® in Canada. Firdapse® is indicated for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. Under the terms of the agreement, Catalyst will supply Firdapse® to KYE and KYE will be responsible for promotion, sales, advertisement, marketing, product importation and distribution. KYE will also be responsible for the ongoing maintenance of the regulatory file and future communications with Health Canada.

Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce Agreement to Make Firdapse® (amifampridine phosphate) Available to LEMS Patients in Canada

Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q2 2020 Results - Earnings Call Transcript

Firdapse fails to hit the mark in the clinic yet again.

Why Catalyst Pharmaceuticals Stock Is Crashing Today

Catalyst (CPRX) beats both earnings and sales estimates in the second quarter of 2020.

News for Catalyst Pharmaceuticals Stock (CPRX)